Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR7 | Q9NYK1 | 19/20 | 0.65 |
| ▸ | TLR8 | Q9NR97 | 8/20 | 0.65 |
| ▸ | NUDT1 | P36639 | 2/20 | 0.63 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | HRH2 | P25021 | 1/20 | 0.46 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.46 |
| ▸ | HTR2A | P28223 | 1/20 | 0.46 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.46 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.46 |
| ▸ | HTR2B | P41595 | 1/20 | 0.46 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.46 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28909406 | 0.90 | TLR7 (0.62) | TLR7TLR8NUDT1 | |
| SCHEMBL31411154 | 0.86 | TLR7 (0.63) | TLR7TLR8NUDT1LMNAPOLB | |
| SCHEMBL16802235 | 0.84 | TLR7 (0.69) | TLR7TLR8NUDT1 | |
| SCHEMBL22722043 | 0.84 | TLR7 (0.69) | TLR7TLR8NUDT1 | |
| SCHEMBL893024 | 0.84 | TLR7 (0.74) | TLR7TLR8NUDT1LMNAPOLB | |
| SCHEMBL29977522 | 0.84 | TLR7 (0.74) | TLR7TLR8NUDT1LMNAPOLB | |
| SCHEMBL2707329 | 0.84 | TLR7 (0.63) | TLR7TLR8NUDT1LMNAPOLB | |
| SCHEMBL18179117 | 0.83 | TLR7 (0.76) | TLR7TLR8NUDT1 | |
| SCHEMBL18179114 | 0.83 | TLR7 (0.79) | TLR7TLR8NUDT1 | |
| SCHEMBL544735 | 0.83 | TLR7 (0.62) | TLR7TLR8NUDT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210145975-A1 | IMMUNOGENIC COMPOUND | ALTIMMUNE UK LTD (GB) | 2021-05-20 | — | — | US | disclosed |
| US-10849984-B2 | Immunogenic compound | ALTIMMUNE UK LIMITED (GB) | 2020-12-01 | — | — | US | disclosed |
| US-20200038519-A1 | IMMUNOGENIC COMPOUND | ALTIMMUNE UK LIMITED | 2020-02-06 | — | — | US | disclosed |
| US-10434183-B2 | Immunogenic compound | Altimmune UK Ltd. (GB) | 2019-10-08 | — | — | US | disclosed |
| US-20190125889-A1 | IMMUNOGENIC COMPOUND | ALTIMMUNE UK LIMITED (GB) | 2019-05-02 | — | — | US | disclosed |
| US-9962453-B2 | Immunogenic compound | ALTIMMUNE UK LIMITED (GB) | 2018-05-08 | — | — | US | disclosed |
| US-9962453-B2 | Immunogenic compound | ALTIMMUNE UK LIMITED (GB) | 2018-05-08 | — | — | US | disclosed |
| US-20160310603-A1 | IMMUNOGENIC COMPOUND | ALTIMMUNE UK LIMITED (GB) | 2016-10-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200038519-A1 | IMMUNOGENIC COMPOUND | CD74, HLA-DRB1, MICA | TLR7 33/4885TLR8 41/4885NUDT1 3742/4885 |
| US-10434183-B2 | Immunogenic compound | CD74, HLA-DRB1, MICA | TLR7 33/4885TLR8 41/4885NUDT1 3742/4885 |
| US-20190125889-A1 | IMMUNOGENIC COMPOUND | CD74, HLA-DRB1, MICA | TLR7 33/4885TLR8 41/4885NUDT1 3742/4885 |
| US-10849984-B2 | Immunogenic compound | CD74, HLA-DRB1, MICA | TLR7 33/4885TLR8 41/4885NUDT1 3742/4885 |
| US-20210145975-A1 | IMMUNOGENIC COMPOUND | CD74, HLA-DRB1, MICA | TLR7 33/4885TLR8 41/4885NUDT1 3742/4885 |
| US-20160310603-A1 | IMMUNOGENIC COMPOUND | CD74, HLA-DRB1, MICA | TLR7 33/4885TLR8 41/4885NUDT1 3742/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.